P Tynjälä1, P Lahdenne, P Vähäsalo, H Kautiainen, V Honkanen. 1. Hospital for Children and Adolescents, Helsinki University Central Hospital, Research Unit, Lastenlinnantie 11 C 29, PL 280, 00029 HUS, Finland. pirjo.tynjala@hus.fi
Abstract
OBJECTIVES: To evaluate the impact of anti-tumour necrosis factor (TNF) treatment on growth and to identify the predictors for the change in growth in severe juvenile idiopathic arthritis (JIA). METHODS: Data from 71 JIA patients (43 on etanercept, 28 on infliximab) were reviewed two years before and two years on the anti-TNF treatment. The patients had polyarticular disease course (48 polyarthritis, 19 extended oligoarthritis, two systemic arthritis, and two enthesitis related arthritis). At the initiation of the anti-TNF treatment, their mean age was 9.6 years and the mean duration of JIA, 5.7 years. RESULTS: In the patients with delayed growth before anti-TNF treatment (n = 53), the growth velocity, measured as the change in height standard deviation score, accelerated +0.45 (95% confidence interval, 0.33 to 0.56) (p<0.001) during the anti-TNF treatment. In the patients with normal or accelerated growth before anti-TNF treatment (n = 18), the change in growth velocity was +0.05 (0.07 to 0.16) (p = 0.39). At two years on anti-TNF treatment, the growth velocity between these two groups was similar. No difference was found between the patients treated with etanercept or infliximab. A decelerating growth rate before the anti-TNF treatment was the strongest predictor for the observed increase in the growth velocity. The change in the inflammatory activity remained a significant predictor of the growth velocity even after the decrease in glucocorticoid dose was taken into account. CONCLUSIONS: In the treatment of polyarticular JIA, the anti-TNF treatment not only suppresses inflammation but also restores growth velocity.
OBJECTIVES: To evaluate the impact of anti-tumour necrosis factor (TNF) treatment on growth and to identify the predictors for the change in growth in severe juvenile idiopathic arthritis (JIA). METHODS: Data from 71 JIA patients (43 on etanercept, 28 on infliximab) were reviewed two years before and two years on the anti-TNF treatment. The patients had polyarticular disease course (48 polyarthritis, 19 extended oligoarthritis, two systemic arthritis, and two enthesitis related arthritis). At the initiation of the anti-TNF treatment, their mean age was 9.6 years and the mean duration of JIA, 5.7 years. RESULTS: In the patients with delayed growth before anti-TNF treatment (n = 53), the growth velocity, measured as the change in height standard deviation score, accelerated +0.45 (95% confidence interval, 0.33 to 0.56) (p<0.001) during the anti-TNF treatment. In the patients with normal or accelerated growth before anti-TNF treatment (n = 18), the change in growth velocity was +0.05 (0.07 to 0.16) (p = 0.39). At two years on anti-TNF treatment, the growth velocity between these two groups was similar. No difference was found between the patients treated with etanercept or infliximab. A decelerating growth rate before the anti-TNF treatment was the strongest predictor for the observed increase in the growth velocity. The change in the inflammatory activity remained a significant predictor of the growth velocity even after the decrease in glucocorticoid dose was taken into account. CONCLUSIONS: In the treatment of polyarticular JIA, the anti-TNF treatment not only suppresses inflammation but also restores growth velocity.
Authors: C Polito; C G Strano; A N Olivieri; M Alessio; C S Iammarrone; N Todisco; M R Papale Journal: Scand J Rheumatol Date: 1997 Impact factor: 3.641
Authors: D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck Journal: N Engl J Med Date: 2000-03-16 Impact factor: 91.245
Authors: O Borrelli; C Bascietto; F Viola; M Bueno de Mesquita; M Barbato; V Mancini; S Bosco; S Cucchiara Journal: Dig Liver Dis Date: 2004-05 Impact factor: 4.088
Authors: A Diamanti; M S Basso; M Gambarara; B Papadatou; F Bracci; C Noto; M Castro Journal: Int J Colorectal Dis Date: 2008-09-17 Impact factor: 2.571
Authors: Jaime Guzman; Tristan Kerr; Leanne M Ward; Jinhui Ma; Kiem Oen; Alan M Rosenberg; Brian M Feldman; Gilles Boire; Kristin Houghton; Paul Dancey; Rosie Scuccimarri; Alessandra Bruns; Adam M Huber; Karen Watanabe Duffy; Natalie J Shiff; Roberta A Berard; Deborah M Levy; Elizabeth Stringer; Kimberly Morishita; Nicole Johnson; David A Cabral; Maggie Larché; Ross E Petty; Ronald M Laxer; Earl Silverman; Paivi Miettunen; Anne-Laure Chetaille; Elie Haddad; Lynn Spiegel; Stuart E Turvey; Heinrike Schmeling; Bianca Lang; Janet Ellsworth; Suzanne E Ramsey; Johannes Roth; Sarah Campillo; Susanne Benseler; Gaëlle Chédeville; Rayfel Schneider; Shirley M L Tse; Roxana Bolaria; Katherine Gross; Debbie Feldman; Bonnie Cameron; Roman Jurencak; Jean Dorval; Claire LeBlanc; Claire St Cyr; Michele Gibbon; Rae S M Yeung; Ciarán M Duffy; Lori B Tucker Journal: Pediatr Rheumatol Online J Date: 2017-08-22 Impact factor: 3.054
Authors: Nirit Mor-Vaknin; Miguel Rivas; Maureen Legendre; Smriti Mohan; Ye Yuanfan; Theresa Mau; Anne Johnson; Bin Huang; Lili Zhao; Yukiko Kimura; Steven J Spalding; Paula W Morris; Beth S Gottlieb; Karen Onel; Judyann C Olson; Barbara S Edelheit; Michael Shishov; Lawrence K Jung; Elaine A Cassidy; Sampath Prahalad; Murray H Passo; Timothy Beukelman; Jay Mehta; Edward H Giannini; Barbara S Adams; Daniel J Lovell; David M Markovitz Journal: Arthritis Rheumatol Date: 2018-02-22 Impact factor: 10.995